George Atiee

847 total citations
24 papers, 618 citations indexed

About

George Atiee is a scholar working on Infectious Diseases, Molecular Biology and Pharmacology. According to data from OpenAlex, George Atiee has authored 24 papers receiving a total of 618 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Infectious Diseases, 5 papers in Molecular Biology and 4 papers in Pharmacology. Recurrent topics in George Atiee's work include Antifungal resistance and susceptibility (3 papers), Allergic Rhinitis and Sensitization (2 papers) and Antimicrobial Resistance in Staphylococcus (2 papers). George Atiee is often cited by papers focused on Antifungal resistance and susceptibility (3 papers), Allergic Rhinitis and Sensitization (2 papers) and Antimicrobial Resistance in Staphylococcus (2 papers). George Atiee collaborates with scholars based in United States, Japan and Germany. George Atiee's co-authors include Sue G. Griffith, Martin Koller, Daniel Ness, Gene G. Kinney, Michael Grundman, Dale B. Schenk, Susanne Ostrowitzki, Jay Soto, Wagner Zago and Gail Murphy and has published in prestigious journals such as PLoS ONE, The FASEB Journal and Journal of Allergy and Clinical Immunology.

In The Last Decade

George Atiee

23 papers receiving 599 citations

Peers

George Atiee

NEURO

EDM

EPIDE

SURGE

CMN

Peter Hildenbrand United States

Francesca Sciarra Italy

Thomas Lavaux France

Jenna M. Bartley United States

Li Cheng China

Guo-En Yao China

Kaiyu Wang China

Marija Djukic Germany

Fabrice Chrétien France

Peter Hildenbrand United States

George Atiee

221 ×1.3

NEURO

69 ×0.5

EDM

92 ×0.7

EPIDE

37 ×0.3

SURGE

51 ×0.5

CMN

Citations per year, relative to George Atiee George Atiee (= 1×) peers Peter Hildenbrand

Countries citing papers authored by George Atiee

Since Specialization

Citations

This map shows the geographic impact of George Atiee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by George Atiee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites George Atiee more than expected).

Fields of papers citing papers by George Atiee

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by George Atiee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by George Atiee. The network helps show where George Atiee may publish in the future.

Co-authorship network of co-authors of George Atiee

This figure shows the co-authorship network connecting the top 25 collaborators of George Atiee. A scholar is included among the top collaborators of George Atiee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with George Atiee. George Atiee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bulitta, Jürgen B., Edward Fang, Martín E. Stryjewski, et al.. (2024). Population pharmacokinetic rationale for intravenous contezolid acefosamil followed by oral contezolid dosage regimens. Antimicrobial Agents and Chemotherapy. 68(4). e0140023–e0140023. 3 indexed citations

Ahmadi, Ali Reza, George Atiee, Andrew M. Cameron, et al.. (2023). A phase I, first-in-human study to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics of MRG-001 in healthy subjects. Cell Reports Medicine. 4(9). 101169–101169. 3 indexed citations

Zhou, Jin, Tharin Limsakun, Ophelia Yin, et al.. (2019). First‐in‐Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of an Oral Formulation of DS‐1040, an Inhibitor of the Activated Form of Thrombin‐Activatable Fibrinolysis Inhibitor, in Healthy Subjects. The Journal of Clinical Pharmacology. 59(12). 1669–1677. 9 indexed citations

Lu, Lucy, Michael Ryan, Mark Harnett, George Atiee, & Scott A. Reines. (2019). Comparing the Pharmacokinetics of 2 Novel Intravenous Tramadol Dosing Regimens to Oral Tramadol: A Randomized 3‐Arm Crossover Study. Clinical Pharmacology in Drug Development. 9(4). 537–546. 8 indexed citations

Chen, Jun, et al.. (2019). A Phase 1, Single-Dose, Open-Label, 5-Treatment, Crossover, Pharmacokinetic Study of Comparative Bioavailability of Epinephrine Nasal Spray and EpiPen® in Healthy Adults With Seasonal Allergies. Journal of Allergy and Clinical Immunology. 143(2). AB144–AB144. 3 indexed citations

Christiansen, Mark P., Leslie J. Klaff, Ronald Brazg, et al.. (2018). A Prospective Multicenter Evaluation of the Accuracy of a Novel Implanted Continuous Glucose Sensor: PRECISE II. Diabetes Technology & Therapeutics. 20(3). 197–206. 105 indexed citations

Tachibana, Masaya, Naotoshi Yamamura, George Atiee, et al.. (2018). Coadministration of probenecid and cimetidine with mirogabalin in healthy subjects: A phase 1, randomized, open‐label, drug–drug interaction study. British Journal of Clinical Pharmacology. 84(10). 2317–2324. 14 indexed citations

Zhou, Jin, Jarema Kochan, Ophelia Yin, et al.. (2017). A first‐in‐human study of DS‐1040, an inhibitor of the activated form of thrombin‐activatable fibrinolysis inhibitor, in healthy subjects. Journal of Thrombosis and Haemostasis. 15(5). 961–971. 26 indexed citations

Duchin, Kenneth L., Anil Duggal, George Atiee, et al.. (2017). An Open-Label Crossover Study of the Pharmacokinetics of the 60-mg Edoxaban Tablet Crushed and Administered Either by a Nasogastric Tube or in Apple Puree in Healthy Adults. Clinical Pharmacokinetics. 57(2). 221–228. 13 indexed citations

10.

Atiee, George, et al.. (2017). A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of DS-3801b, a Motilin Receptor Agonist, in Healthy Subjects. The Journal of Clinical Pharmacology. 57(9). 1221–1230. 5 indexed citations

11.

Schenk, Dale B., Martin Koller, Daniel Ness, et al.. (2016). First‐in‐human assessment of PRX002, an anti–α‐synuclein monoclonal antibody, in healthy volunteers. Movement Disorders. 32(2). 211–218. 185 indexed citations

12.

Woodyer, Ryan D., et al.. (2014). A single‐dose, microtracer study to determine the mass balance of orally administered, ¹⁴ C‐labeled sweetener in healthy adult men (LB450). The FASEB Journal. 28(S1).

13.

Nunez, Derek J., Mark Bush, David Collins, et al.. (2014). Gut Hormone Pharmacology of a Novel GPR119 Agonist (GSK1292263), Metformin, and Sitagliptin in Type 2 Diabetes Mellitus: Results from Two Randomized Studies. PLoS ONE. 9(4). e92494–e92494. 56 indexed citations

14.

Hopkins, Robert J., Edward W. Bernton, Gabriel Meister, et al.. (2014). Efficacy and Safety of AVP-21D9, an Anthrax Monoclonal Antibody, in Animal Models and Humans. Antimicrobial Agents and Chemotherapy. 58(7). 3618–3625. 14 indexed citations

15.

Nayak, Anjuli, et al.. (2012). Safety of ragweed sublingual allergy immunotherapy tablets in adults with allergic rhinoconjunctivitis. Allergy and Asthma Proceedings. 33(5). 404–410. 25 indexed citations

16.

Atiee, George, Kenneth C. Lasseter, Amy McCullough, et al.. (2011). Absence of Pharmacokinetic Interaction Between Intravenous Peramivir and Oral Oseltamivir or Rimantadine in Humans. The Journal of Clinical Pharmacology. 52(9). 1410–1419. 13 indexed citations

17.

Pentikis, Helen S., Mark Matson, George Atiee, et al.. (2011). Pharmacokinetics and Safety of FV-100, a Novel Oral Anti-Herpes Zoster Nucleoside Analogue, Administered in Single and Multiple Doses to Healthy Young Adult and Elderly Adult Volunteers. Antimicrobial Agents and Chemotherapy. 55(6). 2847–2854. 33 indexed citations

18.

Luo, Wen‐Lin, Tami Crumley, David L. Ebel, et al.. (2010). Single Therapeutic and Supratherapeutic Doses of Laropiprant, a Selective Prostaglandin D₂ Receptor 1 Antagonist, Do Not Prolong the QTcF Interval in Healthy Volunteers. The Journal of Clinical Pharmacology. 50(11). 1273–1279. 2 indexed citations

19.

Dishy, Victor, Fang Liu, David L. Ebel, et al.. (2009). Effects of Aspirin When Added to the Prostaglandin D₂ Receptor Antagonist Laropiprant on Niacin‐Induced Flushing Symptoms. The Journal of Clinical Pharmacology. 49(4). 416–422. 16 indexed citations

20.

Matson, Mark, et al.. (2009). A Study of the Safety and Pharmacokinetics of Single and Multiple Doses of FV-100 in Subjects 65 Years and Over. Antiviral Research. 82(2). A49–A49. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact